Algernon's DMT Stroke Study Gets FDA Praise 🚀

Algernon Pharmaceuticals (CSE: AGN – OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news the company has heard back from the FDA in regard to the company investigating the use of DMT in the rehabilitation of stroke.

Moreau telling Proactive the FDA provided valuable input into the design of the Company’s planned Phase 1 clinical trial, which will be conducted through Hammersmith Medicines Research in the UK, in Q4 2021.